EVX-01 induced positive clinically relevant immune responses in all assessed patientsBooster immunizations tended to increase the immune responseThe observed immune responses were mediated by both CD4+ and CD8+ T-cells COPENHAGEN, Denmark, May 23, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting, where it will present positive immune data form its ongoing EVX-01 Phase 2 study.

EVX-01在所有评估患者中诱导阳性临床相关免疫应答加强免疫倾向于增加免疫应答观察到的免疫应答是由CD4+和CD8+T细胞介导的丹麦哥本哈根，2024年5月23日（环球通讯社）-Evaxion Biotech A/S（纳斯达克：EVAX）（“Evaxion”或“公司”），一家专门开发AI Immunology™动力疫苗的临床阶段TechBio公司，今天宣布参加美国临床肿瘤学会（ASCO）年会，将从其正在进行的EVX-01第二阶段研究中提供阳性免疫数据。

The study assesses the personalized cancer vaccine EVX-01 in combination with anti-PD1 therapy in patients with advanced melanoma. The conference will take place in Chicago, IL, from May 31 – June 4, 2024.  “We continue to see encouraging results from our ongoing Phase 2 study with EVX-01. The immune signatures induced by EVX-01 are both specific and strong, with booster immunizations pointing to further increased immune responses.

该研究评估了个性化癌症疫苗EVX-01联合抗PD1治疗晚期黑色素瘤患者。会议将于2024年5月31日至6月4日在伊利诺伊州芝加哥举行。“我们继续看到正在进行的EVX-01第二阶段研究的令人鼓舞的结果。EVX-01诱导的免疫特征既特异又强，加强免疫指向进一步增加的免疫应答。

The data makes us optimistic about the potential clinical benefit of EVX-01, and we eagerly await further data readouts on this novel personalized cancer vaccine. With our AI-Immunology™ platform, we can precisely select vaccine targets and design personalized vaccines that match each patient’s unique tumor signature and immune characteristics.

这些数据使我们对EVX-01的潜在临床益处感到乐观，我们急切地等待这种新型个性化癌症疫苗的进一步数据读数。利用我们的AI Immunology™平台，我们可以精确选择疫苗靶标，并设计符合每位患者独特肿瘤特征和免疫特征的个性化疫苗。

This represents a novel approach to addressing an unmet medical need that remains dire, and we are excited about the interest we are seeing in the EVX-01 program,” said Christian Kanstrup, CEO at Evaxion. This ongoing Phase 2 study currently confirms findings from the previous Phase 1 study, reaffirming the ability of Evaxion’s AI-Immunology™ platform to precisely select therapeutically relevan.

Evaxion首席执行官克里斯蒂安·坎斯特鲁普（ChristianKanstrup）表示：“这代表了一种新的方法，可以解决仍然严峻的未满足的医疗需求，我们对EVX-01计划的兴趣感到兴奋。”。这项正在进行的第二阶段研究目前证实了先前第一阶段研究的结果，重申了Evaxion的AI Immunology™平台精确选择治疗相关药物的能力。